Poster Presentation Australasian Cytometry Society 43rd Annual Conference and Workshop

RISK ASSESSMENT OF MEASURABLE RESIDUAL DISEASE IN CHILDHOOD ALL WITH FLOW CYTOMETRIC METHOD  (#111)

Pınar Akpınar Oktar 1 , Haldun Uz 2 , Seda Demirel 1 , Özlem İşgüzar Karadavut 1 , Üstün Ezer 3 , Muazzez Deniz Sucuoğlu 2 , Türkan Patıroğlu 3 , Ahmet Emin Kürekçi 3
  1. Department of Tissue Typing and Transplantation Immunology, LÖSANTE Children's and Adult Hospital, ANKARA, Turkey, LÖSANTE Children's and Adult Hospital, ANKARA, Turkey
  2. Department of Pediatrics, LÖSANTE Children's and Adult Hospital, ANKARA, Turkey, LÖSANTE Children's and Adult Hospital, ANKARA, Turkey
  3. Department of Pediatric Hematology, LÖSANTE Children's and Adult Hospital, ANKARA, Turkey, LÖSANTE Children's and Adult Hospital, ANKARA, Turkey

In Childhood Acute Lymphoblastic Leukemia, after diagnosis, measurable residual disease (MRD; minimal residual disease) is an important prognostic indicator in risk stratification and treatment planning, together with well-known clinical, cytogenetic and molecular information. MRD can be evaluated using multiparametric flow cytometry and molecular protocols. In this study, the prognostic effect of measurable MRD analysis in the bone marrow using 8-color multiparametric flow cytometry (MFC) was evaluated in patient groups with Childhood Acute Lymphoblastic Leukemia (pre B-ALL / pro B-ALL / B-ALL / T-ALL). 

In the study, 79 patients (6.3% T-ALL patients, 93.7% B-ALL patients) with Childhood Acute Lymphoblastic Leukemia who were treated at Lösante Children's and Adult Hospital between 2017 and 2020, were determined in different time periods after treatment. MRD results were evaluated. With the presence of MRD at any time during the first 100 days, the rate of subsequent recurrence was statistically evaluated. In this study, quantitative evaluation of MRD results in patients with Childhood Acute Lymphoblastic Leukemia is presented. We think that our study will provide guidance for the current and future use of this method in clinical practice.

  1. Ferreira-Facio, Cristiane S., et al. "Contribution of multiparameter flow cytometry immunophenotyping to the diagnostic screening and classification of pediatric cancer." PloS one 8.3 (2013): e55534.
  2. Pulsipher MA, Bader P, Klingebiel T, Cooper LJ. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse. Biol Blood Marrow Transplant 2009; 15(S1): 62–71.
  3. Bastos-Oreiro M 1 , Perez-Corral A, Martínez-Laperche C, Bento L, Pascual C, Kwon M, Balsalobre P, Muñoz C, Buces E, Serrano D, Gayoso J, Buño I, Anguita J, Diéz-Martín JL. , Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acutemyeloid leukemia before and after allogeneic hemopoietic stem cell transplantation. Eur J Haematol. 2014 Sep;93(3):239-46. doi: 10.1111/ejh.12336. Epub 2014 Apr 29
  4. Pigneux A 1 , Montesinos P 2,3 , Cong Z 4 , Zhang X 4 , Pownell AK 5 , Wieffer H 5 , McKendrick J 5,6 , Brüggemann M 7 .Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey. BMC Cancer. 2018 Nov 12;18(1):1100. doi: 10.1186/s12885-018-5002-5.
  5. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030–1043